When administered prophylactically in MMTV-Her2/neu transgenic mice, autochthonous mammary tumor formation was significantly delayed as compared to a control Lm. These results suggest that ISG15 is not only a novel immunotherapeutic target for breast cancer but also that Lm-based vaccines are powerful platforms to validate TAA discovery. Here, ERBB2 is linked to breast carcinoma.